Wall Street is positive on Editas Medicine Inc (EDIT). On average, analysts give Editas Medicine Inc a Buy rating. The average price target is $14.142, which means analysts expect the stock to gain by 74.16% over the next twelve months.
That average ranking earns Editas Medicine Inc an Analyst Rating of 33, which is better than 33% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating EDIT a Buy today. Find out what this means to you and get the rest of the rankings on EDIT!
Fundamental research of the underlying health of a company can be an extremely useful resource when making investment decisions. Analysts observe growth prospects and forecasted earnings of companies to gain a comprehensive view of particular industries. This data allows traders to react before numbers are officially reported.
InvestorsObserver takes the ratings from these analysts and percentile ranks those aveages. This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings.
What's Happening With Editas Medicine Inc Stock Today?
Editas Medicine Inc (EDIT) stock is trading at $8.12 as of 9:57 AM on Tuesday, Nov 14, a rise of $0.47, or 6.14% from the previous closing price of $7.65. The stock has traded between $7.66 and $8.40 so far today. Volume today is less active than usual. So far 190,764 shares have traded compared to average volume of 1,603,579 shares.
Click Here to get the full Stock Report for Editas Medicine Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
